title: [Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer].
abstract: OBJECTIVE
  To assess the feasibility of [(18)F]fluoroerythronitroimidazole ((18)F-FETNIM) with integrated positron emission tomography and computed tomography (PET-CT) imaging in detection of hypoxia in non-small-cell lung cancer (NSCLC) patients.
  
  
  METHODS
  Forty-two patients with newly diagnosed NSCLC underwent (18)F-FETNIM PET-CT before treatment. Nineteen patients rested for approximately 120 minutes before undergoing PET-CT, 23 patients underwent 2 sequential PET-CT scans at 60 minutes and 120 minutes after intravenous injection (18)F-FETNIM. (18)F-FETNIM uptake was quantified by calculating the maximum standardized uptake value in the tumor (SUVmax-T) and contralateral normal lung tissue (SUVmax-N). Regions of interest (ROIs) were drawn in the tumor and contralateral position and the radioactivity ratio of tumor to normal (T/N) was calculated.
  
  
  RESULTS
  SUVmax-T (2.43 +/- 1.34) was significantly higher than SUVmax-N (0.87 +/- 0.46, P < 0.001) at 120 min. SUVmax-T (2.80 +/- 1.09) and SUVmax-N (1.16 +/- 0.56) at 60 min were significantly higher than SUVmax-T (2.61 +/- 1.10) and SUVmax-N (P < 0.01) at 120 min. T/N (2.56 +/- 0.71) at 60 min was higher than that at 120 min (2.48 +/- 0.60), but the difference between them was not significant (P = 0.324).
  
  
  CONCLUSIONS
  Our results indicate that (18)F-FETNIM PET-CT may be a useful tool for evaluating hypoxia and may be a means to target specifically tumor cells resistant to conventional treatment before and during ongoing therapy in NSCLC.
authors.affiliation: Department of Radiation Oncology, Shandong Tumor Hospital, Jinan 250117, China.
authors.forename: Man
authors.initials: M
authors.lastname: Hu
authors.forename: Li
authors.initials: L
authors.lastname: Kong
authors.forename: Shu-Qiang
authors.initials: SQ
authors.lastname: Zhao
authors.forename: Guo-Ren
authors.initials: GR
authors.lastname: Yang
authors.forename: Wen-Feng
authors.initials: WF
authors.lastname: Yang
authors.forename: An-Qin
authors.initials: AQ
authors.lastname: Han
authors.forename: Zheng
authors.initials: Z
authors.lastname: Fu
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.forename: Jin-Song
authors.initials: JS
authors.lastname: Zheng
authors.forename: Jin-Ming
authors.initials: JM
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology; D015687:Cell Hypoxia; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009593:Nitroimidazoles; D049268:Positron-Emission Tomography / Q000379:methods*; D014057:Tomography, X-Ray Computed
chemical_list: D009593:Nitroimidazoles; C092114:fluoroerythronitroimidazole